Loading...
XSHE
300630
Market cap190mUSD
Mar 21, Last price  
2.49CNY
Name

Hainan Poly Pharm Co Ltd

Chart & Performance

D1W1MN
XSHE:300630 chart
No data to show
P/E
16.21
P/S
1.07
EPS
0.15
Div Yield, %
—
Shrs. gr., 5y
1.43%
Rev. gr., 5y
15.89%
Revenues
1.30b
-27.78%
111,180,586132,456,742164,562,185202,822,750248,009,195324,826,689623,904,151950,095,2071,188,603,4241,508,829,4211,806,344,5861,304,483,339
Net income
86m
-79.57%
15,325,75824,790,22436,665,19050,701,92369,778,54698,404,449181,427,309301,147,028407,450,895416,603,057420,615,70785,922,865
CFO
113m
-78.90%
36,941,30045,453,40056,600,46258,137,74655,529,91693,790,99194,785,675215,374,300332,075,817157,031,382534,294,809112,719,141
Dividend
Jul 18, 20230.078721 CNY/sh

Profile

Hainan Poly Pharm. Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. The company offers APIs. The company offers formulations in various therapeutic areas, which include anti-allergy, non-steroid anti-inflammatory, antibiotic, and digestive drugs. Its products include desloratadine preparations in anti-allergy drugs, diclofenac preparations in non-steroidal anti-inflammatory drugs, azithromycin for injection and clarithromycin preparations in antibiotic drugs, and trimebutine maleate preparations in digestive drugs. The company was founded in 1992 and is based in Haikou, China.
URL
http://www.hnpoly.com/
IPO date
Mar 28, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,304,483
-27.78%
1,806,345
19.72%
Cost of revenue
1,102,106
1,284,254
Unusual Expense (Income)
NOPBT
202,377
522,090
NOPBT Margin
15.51%
28.90%
Operating Taxes
(11,103)
18,301
Tax Rate
3.51%
NOPAT
213,480
503,790
Net income
85,923
-79.57%
420,616
0.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
(46,411)
(1)
BB yield
0.45%
0.00%
Debt
Debt current
384,613
800,801
Long-term debt
1,530,220
1,490,427
Deferred revenue
153,504
116,981
Other long-term liabilities
(1)
1
Net debt
1,497,339
1,495,364
Cash flow
Cash from operating activities
112,719
534,295
CAPEX
(548,146)
Cash from investing activities
(565,992)
Cash from financing activities
(26,716)
742,872
FCF
325,893
(347,006)
Balance
Cash
401,591
777,705
Long term investments
15,902
18,159
Excess cash
352,269
705,546
Stockholders' equity
1,780,687
2,158,701
Invested Capital
4,619,376
4,422,217
ROIC
4.72%
13.02%
ROCE
4.03%
10.05%
EV
Common stock shares outstanding
452,226
467,351
Price
22.62
-8.27%
24.66
-55.20%
Market cap
10,229,343
-11.24%
11,524,870
-52.25%
EV
11,726,682
13,020,235
EBITDA
382,258
633,653
EV/EBITDA
30.68
20.55
Interest
54,363
40,152
Interest/NOPBT
26.86%
7.69%